ON
ONCSQ.US OncoSec Medical Incorporated
- Market cap
- USD 59.00
- P/E
- -
- P/B
- 0.83x
- ROE
- -
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jan 2023.
Is ONCSQ.US undervalued?
Graham numberThe Graham number of OncoSec Medical Incorporated cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
OncoSec Medical Incorporated fundamental analysis
No fundamental analysis for OncoSec Medical Incorporated yet.
OncoSec Medical Incorporated stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About OncoSec Medical Incorporated
OncoSec Medical Incorporated, a late-stage immuno-oncology company, focuses on designing, developing, commercializing intra-tumoral DNA-based therapeutics to stimulate and augment anti-tumor immune responses for the treatment of cancer. The company's product pipeline includes KEYNOTE-695, which is in Phase 2 trial for the treatment of advanced melanoma; TAVO + SARS-CoV-2 spike glycoprotein, which is in Phase 1 clinical trial for the treatment of COVID-19; and TAVO + epacados…
Full company profileOncoSec Medical Incorporated financial statements
2023 annualized: Fiscal year 2023 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jan 31, 2023, the balance sheet is the latest quarter. Figures change when the annual report is published.
OncoSec Medical Incorporated annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | - | - | - | - | - | - | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | - | - | - | - | - | - | -244K | -990K | -1.08M | -1.07M | -753K |
| Operating Income | -7.06M | -11.9M | -21.2M | -26.9M | -21.4M | -36.1M | -30.4M | -43.4M | -48.4M | -37.0M | -29.9M |
| EBITDA | -6.33M | -11.2M | -20.6M | -26.5M | -21.1M | -32.4M | -30.0M | -42.2M | -46.5M | -36.4M | -29.1M |
| Net Income | -7.15M | -12.0M | -21.2M | -26.9M | -21.4M | -39.1M | -30.3M | -42.3M | -45.2M | -34.2M | -29.8M |
| EPS | -295 | -277 | -368 | -358 | -234 | -215 | -94 | -56 | -30 | -19 | -1,154 |
| Balance Sheet | |||||||||||
| Total Assets | 6.51M | 39.4M | 35.6M | 32.4M | 15.2M | 30.2M | 29.9M | 29.9M | 56.3M | 21.9M | 8.87M |
| Total Liabilities | 1.77M | 1.32M | 2.89M | 4.35M | 4.54M | 7.32M | 5.61M | 16.0M | 18.2M | 15.8M | 14.4M |
| Shareholders' Equity | 4.74M | 38.1M | 32.7M | 28.1M | 10.7M | 22.9M | 24.3M | 13.9M | 38.1M | 6.12M | -5.49M |
| Cash & Short-term Investments | 4.97M | 37.9M | 32.0M | 28.7M | 11.4M | 27.0M | 25.1M | 20.4M | 46.0M | 12.3M | 3.68M |
| Total Debt | - | - | - | - | - | - | 83.8K | 7.82M | 7.32M | 6.17M | 3.46M |
| Cash Flow | |||||||||||
| Operating Cash Flow | -5.53M | -8.98M | -17.7M | -17.8M | -17.3M | -23.2M | -29.0M | -33.1M | -41.8M | -32.1M | -25.5M |
| Capital Expenditure | 115K | 513K | 1.43M | 1.55M | 21.6K | 65.2K | 9.88K | 305K | 800K | 245K | 63.8K |
| Free Cash Flow | -5.65M | -9.49M | -19.1M | -19.4M | -17.4M | -23.3M | -29.0M | -33.1M | -42.6M | -32.4M | -25.5M |
| Ratios | |||||||||||
| ROE | -150.9% | -31.6% | -65.0% | -95.8% | -200.5% | -170.7% | -124.7% | -304.6% | -118.6% | -558.6% | - |
| ROA | -109.8% | -30.5% | -59.7% | -83.0% | -140.8% | -129.4% | -101.3% | -141.3% | -80.3% | -156.2% | -336.4% |
| Debt to Equity | - | - | - | - | - | - | 0.00x | 0.56x | 0.19x | 1.01x | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Debt to Equity
- Total debt divided by shareholders' equity.
OncoSec Medical Incorporated dividends
- Dividend yield
- -
- Forward dividend
- -
- Payout ratio
- -
- Ex-dividend date
- -
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2022 | - | - | - |
| 2021 | - | - | - |
| 2020 | - | - | - |
| 2019 | USD 567.00 | 0.00 | - |
| 2018 | - | - | - |
| 2017 | - | - | - |
| 2016 | - | - | - |
| 2015 | - | - | - |
| 2014 | - | - | - |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 1:22 on Nov 9, 2022.
Who owns OncoSec Medical Incorporated
Ownership data of OncoSec Medical Incorporated is not available yet.
OncoSec Medical Incorporated company profile
- Company name
- OncoSec Medical Incorporated
- Ticker
- ONCSQ.US
- Exchange
- USA Stocks
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 40
- Fiscal year end
- July
- Address
- 24 North Main Street, Pennington, NJ, United States, 08534
- Phone
- 855 662 6732
- Website
- oncosec.com
About OncoSec Medical Incorporated
OncoSec Medical Incorporated, a late-stage immuno-oncology company, focuses on designing, developing, commercializing intra-tumoral DNA-based therapeutics to stimulate and augment anti-tumor immune responses for the treatment of cancer. The company's product pipeline includes KEYNOTE-695, which is in Phase 2 trial for the treatment of advanced melanoma; TAVO + SARS-CoV-2 spike glycoprotein, which is in Phase 1 clinical trial for the treatment of COVID-19; and TAVO + epacadostat + pembrolizumab, which is in Phase 1 clinical trial for the treatment of squamous cell carcinoma head and neck cancer. Its pipeline also comprises TAVO +nivolumab, which is in Phase 2 clinical trial for the treatment of breast cancer; TAVO + CXCL9 for the treatment of solid tumors; and OMS-100 and OMS-102, which are in Phase 2 clinical trial for the treatment of metastatic melanoma. OncoSec Medical Incorporated has clinical trial collaborations with Merck & Co., Inc. and its subsidiary in connection with the KEYNOTE-695 and KEYNOTE-890; and a research collaboration with Duke University's Center for Applied Therapeutics to evaluate TAVO in combination or sequenced with a HER2-plasmid vaccine. The company was formerly known as NetVentory Solutions Inc. and changed its name to OncoSec Medical Incorporated in March 2011. OncoSec Medical Incorporated was incorporated in 2008 and is headquartered in Pennington, New Jersey. On June 14, 2023, OncoSec Medical Incorporated filed a voluntary petition for liquidation under Chapter 7 in the U.S. Bankruptcy Court for the District of New Jersey.